Carl-Johan Spak

Atrogi AB is a company that engages in research and development, and develops and sells products related to type 2 diabetes. The company is based in Solna, Sweden. Atrogi was founded in 2013 by Andreas Bhagwani and Tore Bengtsson. Alexandra Ekman Ryding has been the CEO of the Swedish company since 2018.

Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château.

Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden.

Atrogi AB is a company that engages in research and development, and develops and sells products related to type 2 diabetes. The company is based in Solna, Sweden. Atrogi was founded in 2013 by Andreas Bhagwani and Tore Bengtsson. Alexandra Ekman Ryding has been the CEO of the Swedish company since 2018.

Atrogi AB is a company that engages in research and development, and develops and sells products related to type 2 diabetes. The company is based in Solna, Sweden. Atrogi was founded in 2013 by Andreas Bhagwani and Tore Bengtsson. Alexandra Ekman Ryding has been the CEO of the Swedish company since 2018.

Atrogi AB is a company that engages in research and development, and develops and sells products related to type 2 diabetes. The company is based in Solna, Sweden. Atrogi was founded in 2013 by Andreas Bhagwani and Tore Bengtsson. Alexandra Ekman Ryding has been the CEO of the Swedish company since 2018.

Prokarium Ltd. operates as a biopharmaceutical company that focuses on developing vaccination solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company is headquartered in Keele, the United Kingdom.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Provell Pharmaceuticals LLC is a healthcare company, which engages in marketing and distribution of pharmaceutical products. It offers products of Merck KGaA including Euthyrox. The company was founded by Jim Small and Kurt Kalm in 2005 and is headquartered in Honey Brook, PA.

Provell Pharmaceuticals LLC is a healthcare company, which engages in marketing and distribution of pharmaceutical products. It offers products of Merck KGaA including Euthyrox. The company was founded by Jim Small and Kurt Kalm in 2005 and is headquartered in Honey Brook, PA.

Atrogi AB is a company that engages in research and development, and develops and sells products related to type 2 diabetes. The company is based in Solna, Sweden. Atrogi was founded in 2013 by Andreas Bhagwani and Tore Bengtsson. Alexandra Ekman Ryding has been the CEO of the Swedish company since 2018.

Prokarium Holdings Ltd. provides management services. The private company is based in London, UK. The British company was founded in 2014. Kristen Albright has been the CEO of the company since 2018.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

Prokarium Holdings Ltd. provides management services. The private company is based in London, UK. The British company was founded in 2014. Kristen Albright has been the CEO of the company since 2018.

Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden.

Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

Atrogi AB is a company that engages in research and development, and develops and sells products related to type 2 diabetes. The company is based in Solna, Sweden. Atrogi was founded in 2013 by Andreas Bhagwani and Tore Bengtsson. Alexandra Ekman Ryding has been the CEO of the Swedish company since 2018.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest.

Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest.

Prokarium Holdings Ltd. provides management services. The private company is based in London, UK. The British company was founded in 2014. Kristen Albright has been the CEO of the company since 2018.

Atrogi AB is a company that engages in research and development, and develops and sells products related to type 2 diabetes. The company is based in Solna, Sweden. Atrogi was founded in 2013 by Andreas Bhagwani and Tore Bengtsson. Alexandra Ekman Ryding has been the CEO of the Swedish company since 2018.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Atrogi AB is a company that engages in research and development, and develops and sells products related to type 2 diabetes. The company is based in Solna, Sweden. Atrogi was founded in 2013 by Andreas Bhagwani and Tore Bengtsson. Alexandra Ekman Ryding has been the CEO of the Swedish company since 2018.

Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest.

Atrogi AB is a company that engages in research and development, and develops and sells products related to type 2 diabetes. The company is based in Solna, Sweden. Atrogi was founded in 2013 by Andreas Bhagwani and Tore Bengtsson. Alexandra Ekman Ryding has been the CEO of the Swedish company since 2018.